Clinical Trials Sponsored by Astex Pharmaceuticals

Total 19531 results

Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of TAS1440 With ATRA in Subjects With r/r AML

Acute Myeloid Leukemia

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Solid Tumor

United States
Astex Pharmaceuticals, Inc.

Completed

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United States, Spain, Korea, Republic of, France, Denmark, Canada, Germany, Italy, Czechia, United Kingdom, Poland, Japan, Sweden, Belgium
Astex Pharmaceuticals, Inc.

Terminated

Guadecitabine Extension Study

Acute Myeloid Leukemia | Myeloid Dysplastic Syndrome

United States, Taiwan, Korea, Republic of, Canada, Spain, Japan, Italy, Austria, Denmark
Astex Pharmaceuticals, Inc.

Terminated

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Astex Pharmaceuticals, Inc.

Completed

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Solid Tumors

United States
Astex Pharmaceuticals, Inc.

Completed

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Prostate Cancer

United States, United Kingdom, Spain, Canada
Astex Pharmaceuticals, Inc.

Terminated

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome/Neoplasm

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed/Refractory Peripheral T-cell Lymphoma

Spain, United States, Australia, France, United Kingdom, Italy, Poland
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Terminated

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Combination With Carboplatin in Ovarian Cancer (SGI-110)

Ovarian Cancer

Canada, United States, United Kingdom
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Healthy Volunteers

United States
Astex Pharmaceuticals, Inc.

Completed

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors (SGI-0470-02)

Malignant Disease

United States
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, United Kingdom, Canada
Astex Pharmaceuticals, Inc.

Terminated

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
Astex Pharmaceuticals, Inc.

Recruiting

Study of ASTX029 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States, France, Spain, United Kingdom
Astex Pharmaceuticals, Inc.

Active, not recruiting

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Spain, Canada
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States, Belgium, Spain, Hungary, Italy, Canada, United Kingdom, France
Astex Pharmaceuticals, Inc.

Completed

Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
Astex Pharmaceuticals, Inc.

Enrolling by invitation

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Spain, Canada, Austria, Slovakia, Bulgaria, Hungary
Astex Pharmaceuticals, Inc.

Completed

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Canada, Belgium, Spain, Germany, Denmark, Korea, Republic of, Hungary, France, Japan, Italy, Poland, Sweden, Ukraine, United Kingdom
Astex Pharmaceuticals, Inc.

Completed

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Healthy Volunteers

Netherlands
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
Astex Pharmaceuticals, Inc.

Terminated

Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

Acute Graft Versus Host Disease

United States
Astex Pharmaceuticals, Inc.

Completed

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Healthy Volunteer

United States
Astex Pharmaceuticals, Inc.

Completed

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Healthy Volunteer

United States
Astex Pharmaceuticals, Inc.

Completed

Effect of Food on Blood Levels of ASTX727

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Astex Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Gastrointestinal Stromal Tumor (GIST)

United States
Astex Pharmaceuticals, Inc.

Withdrawn

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Relapsed/Refractory Leukemias

United States
Astex Pharmaceuticals, Inc.

Completed

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Metastatic Solid Tumors

United States
Astex Pharmaceuticals, Inc.

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Non-small Cell Lung Cancer(NSCLC)

United States, Korea, Republic of, Spain, France, Canada
Astex Pharmaceuticals, Inc.

Completed

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer (ESCAPE)

Small Cell Lung Carcinoma

United States, Poland
Astex Pharmaceuticals, Inc.

Completed

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Myelodysplastic Syndrome

United States
Astex Pharmaceuticals, Inc.

Completed

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Tumors

United States
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Emory University
Astex Pharmaceuticals, Inc.

Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Head and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...

United States
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Massachusetts General Hospital
Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Neurological Cancer

United States
University of Nebraska
Astex Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Myelodysplastic Syndromes | Multiple Myeloma | Chronic Lymphocytic Leukemia | Peripheral T-cell Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
US Oncology Research
Astex Pharmaceuticals, Inc.

Completed

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

B-Cell Chronic Lymphocytic Leukemia

United States

Clinical Trials Sponsored by Astex Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations